EFPIA

News

Drugmakers pledge shorter launch times for drugs in EU

Pharmaceutical companies have said they will try to carve months off the time between approval and launch for new medicines in Europe, and reduce disparities in access between countries.

Views & Analysis

Improving Europe’s pharmaceutical regulatory framework

Innovation and access: Improving Europe’s pharmaceutical reg...

EMA “lags behind” other international regulators when it comes to approval timelines, finds EFPIA analysis.

Patients

UK-wide whole genome sequencing for newborns is feasible - b...

Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year ann

R&D

Legal requirement, ethical duty: How to develop compliant, u...

New lay summary guidelines walk sponsors through their obligations under EU regulation No. 536/2014, due to come into force in February next year.

Sales & Marketing

Creating a successful and productive partnership

EFPIA: Partnership is the key to healthcare’s biggest challe...

The European pharma body’s new Health Collaboration Guide hopes to inspire greater partnership working across healthcare, showcasing award-winning collaborations involving Pfizer, Janssen,

News

DNA strand and Cancer Cell Oncology Research Concept 3D rendering

Limited access to cancer biomarker testing in Europe, report...

There is limited access to biomarker testing for cancer in Europe, despite the huge potential of the technology to improve outcomes, according to a new report.